Metrogyl Special Precautions

General: Patients with severe hepatic diseases metronidazole metabolizes slowly, with resultant accumulation of metronidazole and its metabolites in the plasma. Accordingly for such patients, doses below those usually recommended should be administered cautiously.
FC tablet: In known or previously recognized candidiasis Metrogyl may prevent more prominent symptoms during therapy and requires treatment with a candicidal agent.
Use in Pregnancy: Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. Reproduction studies have been performed in rats at doses up to five times the human close and have revealed no evidence of impaired fertility or harm to the fetus due to Metronidazole.
Use in Lactation: Because of the potential for tumorogenicity shown for metronidazole in mouse and rat studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the concentration similar to those found in plasma.
Use in Children: Safety and effectiveness in children have not been established except for the treatment of amoebiasis.
Oral suspension: Mutagenicity studies: Although metronidazole has shown mutagenic activity in a number of in vitro assay systems. Studies in mammals (in vivo) have failed to demonstrate a potential for genetic damage.